Biotech draws pharma giants to platform aimed at developing small molecule drugs that control mRNA translation
Anima Biotech’s discovery phase program to treat Huntington’s disease is one of at least three preclinical programs being partnered with Takeda Pharmaceuticals through an up to $2.4 billion collaboration launched last week. Anima aims to selectively inhibit with small molecules the mutated protein in the HTT gene linked to the rare, inherited disorder. [Anima Biotech]
Anima specializes in treating targets long viewed as “undruggable” by targeting cellular mechanisms that regulate mRNA translation of proteins with specific biological roles in coordinating and regulating translation of individual mRNAs and pathways . . .
